
Yahoo · 30 de oct de 2026
Key TakeawaysRegeneron shares jumped 12% after third-quarter revenue rose 36% to $5. 1 billion.
AMGN
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Últimos 235 días · 12/11/25 — 29/10/26
+52.93%
Precio
$ 25.800
Var. %
+2,06%
Volumen operado
3.645
Precio AMGN
US$ 466,22
Teórico (precio / ratio)
AMGN ÷ 30
US$ 15,54
Yield y fechas del subyacente vía Yahoo Finance. Ver calendario de dividendos.
Yield (USD)
2,2 %
Frecuencia (estimada)
Trim.
Próxima ex-date
19/11
Próximo pago
sin fecha
Cobro estimado (anual)
Dividendo anual USD ÷ ratio 30
USD 0,34
Sí, existe el CEDEAR de AMGN (Amgen Inc.) en la Bolsa de Comercio de Buenos Aires (BYMA). Su ticker local es AMGN.
El ticker del CEDEAR de Amgen Inc. en Argentina es AMGN. La acción subyacente cotiza en NASDAQ con el símbolo AMGN.
El CEDEAR AMGN tiene un ratio de 30:1. Eso significa que 30 CEDEARs equivalen a 1 acción de AMGN.
El CEDEAR AMGN cotiza hoy a $ 25.800 en pesos argentinos, con una variación diaria de +2,06%.
Otros CEDEARs de Salud.

Yahoo · 30 de oct de 2026
Key TakeawaysRegeneron shares jumped 12% after third-quarter revenue rose 36% to $5. 1 billion.

Yahoo · 30 de oct de 2026
The Nasdaq dives Friday as Amazon stock and Intel both plunge on disappointing earnings reports.

Yahoo · 30 de oct de 2026
AstraZeneca beats Q3 earnings and revenue estimates as oncology sales surge 17%, offsetting generic pressure on mature drugs.
Precio de cierre en pesos argentinos. Fuente: data912.
Cotización
US$ 16,48
vs teórico
+6,05%
Cotización MEP implícita
$ 1.565,53
Cotización
US$ 13,82
vs teórico
-11,07%
Cotización Cable implícita
$ 1.866,86
La acción subyacente AMGN (Amgen Inc.) cotiza a US$ 466,22 en su mercado de origen (NASDAQ).
El precio teórico del CEDEAR AMGN se calcula dividiendo el precio de AMGN por el ratio (30). Hoy resulta en US$ 15,54.
En BYMA podés operar AMGN en pesos, AMGND en dólar MEP y AMGNC en dólar cable. Cada modalidad refleja un tipo de cambio distinto.
En esta página encontrás un gráfico con el precio histórico del CEDEAR AMGN en pesos argentinos, con datos de data912.

Yahoo · 30 de oct de 2026
AstraZeneca aims to free up funds to reinvest into its pipeline and meet its goal of $80 billion in annual revenue by 2030.

Yahoo · 30 de oct de 2026
Collecting four figures a month from dividends without ever selling a share sounds straightforward until you price out what it actually costs and see which comp…

SeekingAlpha · 30 de oct de 2026
Amgen appears safe, but the current valuation above $450/share may prove expensive by Q3 2026. Click here to read an analysis of AMGN stock now.

Yahoo · 30 de oct de 2026
For questions about this article or underlying research, email help@trefis.com.

Yahoo · 29 de oct de 2026
The latest trading day saw Amgen (AMGN) settling at $460.73, representing a +1.97% change from its previous close.
Noticias vía Finnhub